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OBJECTIVES This study evaluated the clinical effectiveness of the Medtronic AneuRx stent-graft in patients
with infrarenal abdominal aortic aneurysms (AAAs) who were treated in an endovascular
suite.
BACKGROUND The use of endovascular stent-graft prosthesis for the treatment of AAAs is receiving
increasing attention as an alternative to standard surgical repair. Endovascular treatment of
AAAs offers the potential to avoid the significant morbidity and mortality associated with
surgical repair.
METHODS In this series, 215 patients have undergone AAA exclusion with the AneuRx stent-graft.
Six-month follow-up is available in 132 patients; one-year follow-up is available in 84 and
two-year follow-up in 22.
RESULTS Of the patients, one hundred ninety-two (89%) were male; 87% had hypertension, and 58.6%
were American Society of Anesthesiologists grade IV or higher. The procedural success was
99.5%; we were unable to place the device in one patient. There was no procedural or
one-month mortality. There were no acute conversions to surgical repair. One patient had a
non–Q-wave myocardial infarction 24 h after the procedure. Endoleaks were present in 82
patients (42%) at discharge, 15 patients (11.3%) at six months and 10 patients (11.9%) at one
year. Twenty-two patients had a secondary procedure for endoleak repair of which three were
conversions to surgical repair. Twelve late deaths have occurred, none due to device failure or
AAA rupture. Mean hospital stay was 1.9 days.
CONCLUSIONS These results reveal that infrarenal AAAs can be safely and successfully treated in an
endovascular suite with the AneuRx stent-graft. Further follow-up is needed to determine the
long-term efficacy of endoluminal treatment to prevent rupture and death due to AAAs.
(J Am Coll Cardiol 2001;38:1040–6) © 2001 by the American College of Cardiology
The incidence of abdominal aortic aneurysms (AAAs) is
increasing. The prevalence of AAAs in men over age 65
ranges from 4.3% to 8.8%; if untreated, the natural history
is gradual expansion and possible rupture (1,2). Although
highly effective in preventing such rupture, open surgical
repair is associated with mortality rates of 2% to 8%
(average: 4%) (1,3). Because of the high prevalence of
comorbid medical conditions in patients undergoing surgi-
cal AAA repair, the morbidity rates in high-risk patients can
be as high as 30% (3). Complications include myocardial
infarction, abdominal ischemia, arrhythmias, congestive
heart failure (CHF), pulmonary insufficiency, renal impair-
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ment, bleeding (requiring transfusion), distal thromboem-
bolism and wound infection. Endovascular repair using
stent-grafts is a less invasive procedure that may avoid many
of these risks and has consequently gained increased popu-
larity with both physicians and patients. Endovascular
stent-graft techniques for the repair of AAAs offer less pain,
shorter hospitalization and recovery time (4–6). Stent-graft
treatment of AAAs has advanced rapidly since first used for
endovascular exclusion of an infrarenal AAA by Parodi and
associates (7) in 1990. Although the technology is still in its
infancy, significant improvements have recently been made
in the design and delivery of endovascular stent-grafts.
These improvements in profile and deliverability potentially
lower the possible need for urgent major vascular surgery.
Due to these improvements, we performed these proce-
dures in an endovascular suite as opposed to a surgical
operating room. Therefore, this study evaluated the safety
and short-term clinical effectiveness of the Medtronic
AneuRx stent-graft system in patients with infrarenal
AAAs who were treated in an endovascular suite.
METHODS
Study design and patient population. Patients treated
with the AneuRx system were initially enrolled as part of a
phase III prospective clinical trial. The Institutional Review
Board approved the study protocol as defined by Food and
Drug Administration regulations. Enrollment of patients
began in November 1998. All enrollees provided written
informed consent.
Candidates for the study were selected from patients
referred to cardiology practices at a tertiary medical center.
They had nonruptured infrarenal AAAs that possessed: 1) a
diameter of .5 cm; 2) a diameter of 4.5 to 5.0 cm, with a
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0.5-cm increase during the preceding six months; 3) a
diameter twice that of the normal infrarenal aorta; or 4) a
saccular shape. Additional requirements included a minimal
neck, comprising a 1-cm length of nonaneurysmal aorta,
measuring 18 to 25 mm in diameter and located immedi-
ately inferior to the most inferior major renal artery. Iliac
artery requirements include a luminal caliber that allowed
access with a 21F delivery catheter on one side and a 16F
sheath on the other side and a maximal distal iliac diameter
of 16 mm. Patients had to be willing to undergo follow-up
examination at 1, 6 and 12 months and yearly thereafter.
Exclusion criteria included age ,18 years, an acutely
ruptured aneurysm, pregnant or nursing status, suprarenal
or inflammatory aneurysms, hypercoagulability, active sys-
temic infection, inability to give informed consent and
inability to return for follow-up visits.
Before entering the study, each patient had a complete
history and physical examination. Diagnostic imaging with
contrast computed tomography (CT) and angiography, with
a calibrated pigtail catheter, was performed to characterize
the aneurysm and iliac vessels and to ensure that each
patient met the study qualifications.
Endovascular stent-graft device. The Medtronic AneuRx
stent-graft is a modular, bifurcated system designed to
isolate an aneurysm from blood flow. The outside of the
graft is fully stented, with self-expanding nickel-titanium
stent rings. The graft is made of noncrimped, woven
polyester and is sutured to the nitinol stent. The device
consists of a bifurcated main segment and a contralateral
iliac segment. Additional modular components include
aortic and iliac extender cuffs. The stent-graft is implanted
transluminally in the aortoiliac position via a retrograde
approach from the femoral arteries using AneuRx delivery
catheters: a 21F catheter for the main segment and a 16F
catheter for the iliac segment. The aortic neck of the
bifurcated stent-graft ranges from 20 to 28 mm in diameter.
The main segment of the stent-graft has a proximal aortic
cuff that secures the device in place with a frictional seal.
The straight iliac limbs range from 12 to 16 mm in
diameter. Its length can be adjusted with distal extender
cuffs.
Endovascular treatment procedure. On the basis of diag-
nostic imaging, an endovascular stent-graft of the appropri-
ate size was selected. The aortic and iliac stent-graft device
diameter was oversized by 10% to 20% over what was
measured by CT and angiography. The procedures were
performed in an endovascular suite modified for peripheral
endovascular imaging and interventional procedures. The
endovascular suite is equipped with a floor mounted 16-in.
image intensifier with digital subtraction and roadmapping
capabilities. All procedural imaging was performed with
digital subtraction angiography. The room was designed
and ventilated so that vascular surgical procedures could be
performed with sterile technique. The patients were rou-
tinely prepped as for open surgical repair. All procedures
were performed under general anesthesia. Heparin was
administered intravenously to achieve and maintain an
activated clotting time above 250 s. Access for the 21F
delivery system was via surgical exposure of the femoral
artery or via a percutaneously placed 22F, 20-cm long
sheath (Cook Inc., Bloomington, Indiana). At the end of
the procedure, a vascular surgeon performed femoral artery
repair. Contralateral femoral artery access for the 16F iliac
limb device was obtained percutaneously via a 16F, 30-cm
long sheath with a hemostatic valve (Cook Inc.). When the
deployment of the contralateral iliac limb was completed, a
10F Prostar XL Percutaneous Vascular Surgery Device
(Perclose, Inc., Menlo Park, California) was used for fem-
oral artery closure. After insertion of the stent-graft, a
computerized, power-injected, abdominal aortic and iliac
angiogram with delayed imaging was routinely performed.
If an endoleak was identified and located, additional endo-
vascular treatment was performed. This included balloon
angioplasty or extender cuff placement at the site of the
endoleak. If the abdominal angiogram did not definitively
rule out an endoleak, a selective injection was made in each
limb of the stent-graft in several angulations. An endoleak
is defined as flow of blood into the aneurysm sac between
the endovascular graft and the aortic wall but not into the
abdominal cavity. Interventional cardiologists inserted the
AneuRx stent-graft, and vascular surgeons performed the
arteriotomies and femoral artery repairs in the endovascular
suite.
Patients were extubated in the endovascular suite and
routinely monitored in the cath lab holding area for 1 h to
2 h before they were sent to a telemetry hospital room. They
were not routinely admitted or monitored in the postoper-
ative intensive care unit (ICU). The patients remained in
the hospital overnight for observation. If there were no
contraindications, they were discharged the following day.
All patients underwent flat-plate abdominal radiography
and physical examination before they were discharged from
the hospital.
AneuRx group follow-up protocol. The follow-up imag-
ing protocol changed slightly after the completion of the
phase III trial. During the phase III trial, all the patients
with endoleaks had CT scans with contrast before their
discharge from the hospital. All CT scans were performed
with 3-mm thick slices, delayed images and three-
dimensional reconstruction. After completion of enrollment
in the phase III trial, the protocol was changed so that all
patients had a CT scan with contrast and delayed images
performed at one month after the procedure. In the phase
III trial (first 64 patients), all patients with endoleaks on
Abbreviations and Acronyms
AAA 5 abdominal aortic aneurysm
CHF 5 congestive heart failure
CT 5 computed tomography
ICU 5 intensive care unit
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their predischarge CT scan had repeat CT scans with
contrast at one month. The patients (during the phase III
trial) with no endoleak on their postprocedure digital
subtraction angiogram or predischarge CT scan only had
abdominal duplex ultrasound and plain X-ray imaging at
one month. If the ultrasound was suspicious for endoleak or
the X-ray showed migration of the stent-graft, the patient
had a contrast CT scan performed. The phase III trial
patients all had a contrast CT scan at six months and yearly
afterward, with more frequent CT scans if endoleaks were
detected (Fig. 1).
Since the completion of the phase III trial (next 151
patients), contrast CT scans were performed at one month
in all patients regardless of their postprocedure endoleak
status. If an endoleak was identified, the patient was taken
for angiography. All patients receive contrast CT scans at
six months and yearly thereafter with more frequent CT
scans if an endoleak is identified.
Statistical analysis. Cumulative patency and survival rates
were calculated using the Kaplan-Meyer life table analysis.
Figures are expressed as mean 6 SD where applicable.
RESULTS
Patient characteristics. Between November 1998 and
April 2001, 215 patients were enrolled in the AneuRx
stent-graft study (Table 1). They included 192 men (89%)
and 23 women (11%) whose ages ranged from 48 to 90 years
(mean: 72 6 8.2 years). These patients had multiple
comorbidities, making them a moderate-to-high risk group,
as defined by previous studies (3,8). In 58.6% of the cases,
the American Society of Anesthesiologists operative risk
classification was grade IV or higher (8). Ninety-eight
patients (45.5%) had a history of myocardial infarction; 51
(23.7%) had CHF, and 121 (56.2%) had a history of
coronary revascularization. Ninety-two patients (42.7%) had
chronic obstructive pulmonary disease, and 45 (20.2%) had
a “hostile” abdomen because of previous abdominal surgery
in the area of the aneurysm. The mean AAA diameter was
55.5 6 11 mm (range: 33 to 100 mm). Six-month follow-up
information was available for 132 patients; one-year infor-
mation was available for 84 patients and two-year follow-up
in 22 patients.
Results of the primary procedure. The AneuRx stent-
graft was successfully deployed in 214 patients (Table 2).
The 22F sheath could not be advanced in only one patient
because of diffuse, bilateral, iliac artery atherosclerotic dis-
ease. Before the procedure, 40 patients (18.6%) required
iliac angioplasty to facilitate passage of the 22F sheath. In
174 patients, the Prostar XL device (Perclose Inc., Menlo
Park, California) was used for percutaneous closure of the
femoral artery through which the 16F iliac-limb device had
been delivered. Twenty-six patients had both femoral arter-
ies closed percutaneously with the ProStar XL device. Blood
loss averaged 352 ml per patient; 11 patients (5.1%) required
packed red blood cell transfusions. The mean hospital stay
was 1.9 6 3 days. One hundred thirty-two patients (61.3%)
were discharged home the day after the procedure. Five
patients (2.3%) required postprocedure ICU monitoring;
three had planned aortomonoiliac stent-grafts placed fol-
lowed by femoral to femoral artery bypass and, due to
surgical protocol, were monitored in the postoperative ICU.
Two patients with severe pulmonary disease required grad-
ual recovery from general anesthesia and were monitored in
the postoperative ICU, both for less than 24 h.
Procedural adverse events. No periprocedural deaths or
acute surgical conversions occurred. One patient with a
history of coronary artery disease and CHF had a non–Q-
wave myocardial infarction and CHF 24 h after the proce-
dure. He responded quickly to standard therapy and was
discharged six days after the procedure. Four patients had
femoral or iliac artery dissection related to the 22F sheath:
one dissection required an iliac stent, and the three femoral
artery dissections were repaired at the time of surgical
closure. Five patients had iliac artery thrombotic occlusion
requiring Fogarty thrombectomy immediately after the
procedure; at one-month follow-up examination, they were
without evidence of limb ischemia. No embolic complica-
tions were observed.
Endoleak rates. Endoleaks were classified into four types
(9,10): 1) type I or a perigraft leak due to poor proximal or
distal graft attachment or seal; 2) type II or collateral
backflow due to patent lumbar, inferior mesenteric or
intercostal arteries feeding into the excluded aneurysm sac;
3) type III due to fabric tear, modular or graft disconnection
or graft disintegration; and 4) type IV or transgraft flow
caused by the high porosity of the graft, most likely created
by the numerous suture holes holding the graft material to
the stent. Eighty-two patients (42%) had postprocedure
endoleaks documented by digital subtraction angiography.
Seventy-seven (94%) of these postprocedure endoleaks were
type IV, two (2.4%) were type I, and three (3.6%) were type
II. At one month, all of the type IV endoleaks had resolved.
Of the 132 patients for whom six-month follow-up infor-
mation was available, 15 (11.3%) had endoleaks, 13 of
which were new (Table 3). Of these patients, none had
diameter enlargement of their aneurysm. At one-year
follow-up, 10 of 84 patients (11.9%) had endoleaks, six of
which were new.
Secondary procedures for endoleaks. None of the 77 type
IV endoleaks diagnosed on postprocedure digital subtrac-
tion angiography required treatment; all resolved spontane-
ously (Table 4). Subsequently, 22 patients have required
treatment for endoleaks of which 19 were endovascular
treatments and 3 were conversions to open surgical repair.
One patient had treatment of an endoleak before six-
month follow-up. This patient required two coil emboliza-
tion procedures for a persistent type II endoleak; the first
procedure, documented at one month, was performed for
internal iliac branch collateral backflow, and the second
procedure, documented at six months, was performed for
inferior mesenteric artery branch collateral backflow. De-
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Figure 1. (A) Aortic angiogram from a 72-year-old man, showing a 62-mm infrarenal abdominal aortic aneurysm. (B) Aortic angiogram obtained
immediately after placement of an AneuRx stent-graft. There is no evidence of an endoleak. (C) Three-dimensional reconstruction of a contrast-enhanced,
spiral computed tomographic scan of the abdominal aorta at one-year and (D) two-year follow-up examination. There is no evidence of an endoleak.
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spite the persistent endoleak, this patient’s aneurysm had
not grown.
In the 15 patients who had endoleaks at six months, 13 of
these had no postprocedural or one-month endoleaks. Nine
of the new endoleaks were categorized as type II, due to
collateral back flow. Four of these patients underwent coil
embolization of the collateral vessel. None of these aneu-
rysms has increased in diameter. The other six endoleaks
were categorized as type I, two due to proximal aortic
attachment-site leak and four due to a distal iliac
attachment-site leak. Four of these patients were success-
fully treated with extender cuffs. One patient had to be
converted to open repair because of the inability to advance
a distal extender cuff delivery device to the location of the
leak. The other patient underwent aortic cuff placement but,
because of persistent proximal endoleak and diameter en-
largement of the AAA, was converted to open surgical
repair. The five other patients who had type II endoleaks at
six months had spontaneous closure of their endoleak at
one-year follow-up.
Eight of 10 endoleaks present at one-year follow-up were
due to collateral back flow, of which six underwent coil
embolization of the collateral vessel. The other two type II
endoleaks spontaneously closed at 18-month follow-up.
None of them had diameter enlargement of their aneurysm.
Two patients had a type I endoleak at one year, both
underwent iliac cuff placement and had no endoleak at
18-month follow-up.
Three patients had new endoleaks at two-year follow-up.
Two patients had a type II endoleak, and both underwent
successful coil embolization of the collateral vessel. The
other patient had a type III endoleak due to modular
separation of an aortic cuff and the main body of the stent
graft due to distal migration of the stent graft. Due to
aneurysm enlargement, this patient underwent successful,
uncomplicated conversion to open surgical repair.
Mortality and morbidity. During the first month, there
was no mortality in the AneuRx treated patients. Twelve
late deaths have occurred, all related to comorbid conditions
and not due to device failure or AAA rupture. Six (2.7%)
patients had localized groin infections at the surgical cut
down site requiring antibiotics. Two of these patients
required surgical drainage and intravenous antibiotics.
Twenty patients had mild postprocedural hematomas that
resolved with conservative therapy. No patient had a fem-
oral artery pseudoaneurysm or fistula. Eight patients had
transient femoral neuropathy on the side of femoral artery
cut down; all resolved by one-month follow-up. Five pa-
tients had mild hematuria, and one patient had a lower
urinary tract infection requiring antibiotics. One patient
presented at six months with iliac limb occlusion. He was
successfully treated with Fogarty thrombectomy. He was
also found to have a stenosis in the left iliac limb of the stent
graft, which was treated with angioplasty of the iliac limb.
One patient presented at two-year follow-up with one
month of fever and fatigue. Work-up revealed and infected
AAA sac. The patient had no endoleak on contrast CT.
This patient underwent successful, uncomplicated surgical
Table 1. AneuRx Patients’ Comorbid Conditions
Condition
Number of Patients
(n 5 215) Percentage
Cardiac
Angina 50 23.2
Prior MI 98 45.5
CHF 51 23.7
CABG/PTCA 121 56.2
Other
Obesity 40 18.6
Hypertension 187 86.9
Diabetes mellitus 31 14.4
COPD 92 42.7
CRF 41 19.1
PVD 121 56.2
Tobacco use 168 78.1
Previous abdominal surgery 45 20.2
CABG 5 coronary artery bypass grafting; CHF 5 congestive heart failure; COPD 5
chronic obstructive pulmonary disease; CRF 5 chronic renal failure; MI 5 myocar-
dial infarction; Obesity 5 body mass index $ 30 (24); PTCA 5 percutaneous
transluminal balloon angioplasty; PVD 5 peripheral vascular disease.
Table 2. Primary Procedure Results
Result
AneuRx Patients
(n 5 215) (%)
Procedure success 214 99.5
Access failure 1 0.4
Acute surgical conversion 0 0.0
Percutaneous femoral artery closure (16F) 174/188* 92.5
Percutaneous femoral artery closure (22F) 26/27* 96.2
Average hospital stay (days) 1.81
One-day hospital stay 132† 61.3
In-hospital/one-month mortality 0 0.0
*# successful/# attempted; †discharged the day after the procedure.
Table 3. Endoleaks
Type of Leak
# With Leak/# With F/U (%)
Discharge
82/215
(42%)
6 Months
15/132
(11.3%)
1 Year
10/84
(11.9%)
2 Years
3/22
(13.6%)
Type I, perigraft leak 2 6 2 0
Type II, collateral backflow 3 9 8 2
Type III, fabric tear, modular seal 0 0 0 1
Type IV, transgraft flow 77 0 0 0
F/U 5 follow-up.
Table 4. Follow-Up Results
Result
AneuRx Patients
(n 5 215) (%)
Surgical conversions 4 1.8
Secondary procedures for endoleak 22 10.2
AAA ruptures 0 0.0
AAA related mortality 0 0.0
Non-AAA related mortality 12 5.5
AAA diameter at 1 year (n 5 84)
Reduction 59 70.2
No change 23 27.3
Enlargement 2 2.5
AAA 5 abdominal aortic aneurysm.
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removal of an intact stent-graft, along with surgical repair of
the AAA. Surgical exploration revealed a peptic ulcer that
had eroded into the AAA sac.
Access site closure. The 16F femoral artery access site was
closed percutaneously in 174 patients with a 10F Prostar XL
percutaneous vascular surgery device (11). This percutane-
ous closure technique was attempted in 188 patients, with
successful closure in 174 patients (92.5%). The 14 patients
in whom this procedure failed had surgical repair of the
access site. This technique, using 2 Prostar XL devices, was
attempted to close the 22F access site in 27 patients (12).
Twenty-six of the 27 patients (96%) had successful closure
of the 22F femoral artery access site and, thus, complete
percutaneous AAA repair.
DISCUSSION
The early results for the 215 patients who had AAA repair
with the AneuRx stent-graft in this study compare favorably
with those of previous studies. In a prospective, matched
study of 250 AAA patients, Zarins and colleagues (4)
compared open surgical repair (60 patients) with endovas-
cular repair using the AneuRx stent-graft (190 patients). In
their study, the endoleak rate was 22% before hospital
discharge and 9% at one month. The endoleak rates in this
series were 42% after the procedure and 11.3% at six
months. During the first month, Zarins and associates (4)
reported five deaths (2.6%) in their AneuRx group. There
was no one-month mortality in this series.
The six-month and one-year endoleak rates in this study,
of 11.3% and 11.9%, respectively, compare favorably with
the 9% to 44% rates reported for a variety of endovascular
stent-grafts (5,6,13–18).
Endoleak treatment. Fifteen patients (11.3%) in this series
had endoleaks at six months, and 10 required treatment, but
none had revealed an increase in their aneurysm diameter.
Nine of these endoleaks were type II, four of which were
treated by coil embolization. The five other type II en-
doleaks were followed closely with CT scans because the
collateral artery causing the endoleak was small, and their
AAAs had decreased in diameter. The other six endoleaks
at six months were type I, five of which were successfully
treated with extension cuffs. Due to prior iliac artery
stenting, an AneuRx cuff could not be advanced to the site
of the other type I endoleak, and this patient was converted
to open repair. It is unclear from previous publications what
to do about early type II endoleaks that are not resulting in
aneurysm expansion. Close observation is usually sufficient
initially because some will close spontaneously, as seen in
this study. Type II endoleaks that are resulting in AAA
expansion or are persistent should be treated aggressively.
Current experience supports aggressive treatment of en-
doleaks that are type I or III or that result in aneurysmal
expansion, as this increases the risk of late rupture (19–21).
Endovascular treatment should be attempted first, followed
by open repair if the former strategy is unsuccessful.
Most early endoleaks in this series were type IV occurring
at the time of stent-graft implantation. We were very
aggressive in postdeployment evaluation of endoleaks and
liberal use of extender cuffs and balloon angioplasty to
resolve type I endoleaks. By one month, all of the type IV
endoleaks had closed spontaneously. Transgraft flow, caused
by the high porosity of the Dacron and the numerous suture
holes holding the graft material to the stent, is a transient
phenomenon that terminates spontaneously (4,9,10).
Eight of the 10 endoleaks found at one-year follow-up
were type II. None of these patients had diameter enlarge-
ment of their aneurysms, but two had diameter decrease. Six
of these patients ultimately underwent coil embolization
treatment. Two resolved spontaneously.
Conversion and rupture. Most reports cite a surgical
conversion rate of 2% to 20% (6,13,22,23). To date, four
patients (1.8%) in this study had to undergo open surgical
repair, three due to endoleaks and one due to aneurysm sac
infection. Two of these patients had diameter increase of
their AAA and were the only patients with AAA diameter
enlargement to date. Of the patients with one-year follow-
up, 57 (71.2%) have had aneurismal diameter reduction, and
21 (26.2%) had no change.
No AAA ruptures or AAA-related mortality have oc-
curred in this series with a mean follow-up of 14 6
3 months. A recent article by Zarins et al. (24) reviewed all
1,067 patients in the phase I, II and III portions of the
clinical trial. They found that, in the 1,046 patients who had
successful endovascular AAA repair, aneurysm rupture oc-
curred in seven (0.7%), five of whom died for a rupture-
related mortality of 0.5%. Their mean follow-up was 16
months. Thus, it is imperative that all patients treated with
this device be followed closely. Because of these ruptures,
the threshold for surgical conversion is low for patients with
persistent endoleaks and AAA diameter enlargement.
Thus far, only one case of stent migration has been
observed in this study, but our follow-up period (mean
months: 14 6 3 months) has not allowed adequate time for
full postexclusion aneurysmal morphologic changes to occur
(25).
Wound complications. The six patients who had localized
groin infections at the surgical cut down site were extremely
obese, with body mass indexes over 35 (26). All of these
occurred early in the study and at the surgical femoral artery
access site. Since treating these cases, the preoperative scrub
regimen was changed to include chlorhexidine gluconate
(Hibiclens, Becton Dickinson, Franklin Lakes, New Jersey)
and povidine-iodine (Betadine, Becton Dickinson). All
patients receive oral antibiotics for at least three days after
the procedure. Since these changes have been implemented,
no further groin infections have occurred.
Arterial access site management. We were able to percu-
taneously close 92.5% of the 16F femoral artery access sites
attempted and 96% of the 22F femoral artery sites at-
tempted. Twenty-six patients had complete percutaneous
repair of their AAA. The technique involves the placement
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of Prostar XL percutaneous vascular device before place-
ment of the access sheath with arterial closure after the case.
The arterial access site expands within the confines of the
sutures and, thus, is closed by these sutures at the end of the
case (11,12). Hopefully, with lower profile endovascular
devices and improved percutaneous closure devices for large
bore sheaths, the entire procedure will be routinely per-
formed percutaneously without the need for open surgical
exposure of the femoral arteries.
Conclusions. The early results in this series show that
AAAs can be safely and successfully treated with the
AneuRx stent-graft in an endovascular suite. There is no
increased morbidity and mortality compared with stent-
graft procedures performed in the operating room. There
were no AAA ruptures or acute conversions to open surgical
repair. The majority of the 16F femoral artery access sites
were closed percutaneously, further decreasing the invasive-
ness of the procedure. To date, there are no reliable
long-term follow-up data concerning the durability and
efficacy of the endovascular stent-graft procedure in the
long-term prevention of rupture and death in patients with
AAAs. Nevertheless, owing to the current progress in
endovascular stent-graft design, this less invasive procedure
should soon gain widespread acceptance as an alternative
treatment for selected infrarenal AAAs, especially in pa-
tients at high risk for open surgical repair.
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